71376
document
A trial of d-cycloserine to treat the social deficit in older adolescents and young adults with autism spectrum disorders . Autism spectrum disorders are difficult for older adolescents and young adults as impaired social communication affects the transition to adult life . d-Cycloserine , a partial glycine agonist at the N-methyl-d-aspartic acid receptor , was tested in a double-blind randomized trial in 20 older adolescents and young adults with autism spectrum disorders using two dosing strategies ( 50 mg daily versus 50 mg weekly ) for 8 weeks with a 2-week follow-up after discontinuation . d-Cycloserine caused statistically and clinically significant improvement with no differentiation between dosing strategies on the Social Responsiveness Scale and the Aberrant Behavior Checklist before and after d-cycloserine administration .
71377
Intervention_Pharmacological
d-cycloserine
71378
Intervention_Pharmacological
d-Cycloserine
71379
Intervention_Pharmacological
d-Cycloserine
71380
Intervention_Pharmacological
d-cycloserine
71381
Outcome_Mental
dosing strategies on the Social Responsiveness Scale and the Aberrant Behavior Checklist
71382
Participant_Age
older adolescents
71383
Participant_Age
young adults
71384
Participant_Condition
autism spectrum disorders
71385
Participant_Condition
Autism spectrum disorders
71386
Participant_Age
older adolescents
71387
Participant_Age
young adults
71388
Participant_Sample-size
20
71389
Participant_Age
older adolescents
71390
Participant_Age
young adults
71391
Participant_Condition
autism spectrum disorders